A HUMAN T-CELL LYMPHOKINE CAPABLE OF INTERRUPTING THE PROLIFERATION OF MYELOID LEUKEMIA CELLS AND INDUCING TERMINAL DIFFERENTIATION TO MONOCYTE-MACROPHAGE HAS BEEN DESCRIBED.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$49,925.00
Award Year:
1985
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Award Id:
3082
Agency Tracking Number:
3082
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
10 Skyline Drive, Hawthorne, NY, 10532
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
MATTHEW F. HEIL
PRINCIPAL INVESTIGATOR
(914) 993-4387
Business Contact:
() -
Research Institute:
n/a
Abstract
A HUMAN T-CELL LYMPHOKINE CAPABLE OF INTERRUPTING THE PROLIFERATION OF MYELOID LEUKEMIA CELLS AND INDUCING TERMINAL DIFFERENTIATION TO MONOCYTE-MACROPHAGE HAS BEEN DESCRIBED. THIS ""MATURATION INDUCER'' (OR DIFFERENTIATION FACTOR) IS PRODUCED BY NORMAL T HELPER CELLS AND HAS BEEN SHOWN TO BE A T-CELL MEDIATOR OF MONOCYTIC CELL DEVELOPMENT. THIS ACTIVITY (M.W. 50,000) HAS RECENTLY BEEN PURIFIED BY BIOCHEMICAL PROCEDURES FROM CONDITIONED MEDIUM OF ACTIVATED NORMAL LYMPHOCYTES (INCLUDING OUR LAB) AND FROM A CONTINUOUS T-CELL LINE, HUT-102, AND SHOWN TO BE DISTINCT FROM THE COMMONLY KNOWN LYMPHOKINES INCLUDING INTERFERONS, COLONY STIMULATING FACTORS, MACROPHAGE ACTIVATING FACTOR, ETC. THIS APPLICATION IS AIMED AT THE PRODUCTION OF THIS LYMPHOKINE FOR ITS DEVELOPMENT AND EVALUATION AS AN IMMUNOAUGMENTIVE AGENT WITH POTENTIAL ANTILEUKEMIA ACTIVITY. RAT MONOCLONAL ANTIBODIES THAT HAVE ALREADY BEEN SHOWN TO BIND THE INDUCER ACTIVITY WILL BE EMPLOYED TO CONSTRUCT IMMUNOABSORBENT COLUMNS WHICH WILL BE USED WITH MEDIUM FROM HUT CELLS AND NORMAL LYMPHOCYTE CONDITIONED MEDIUM TO PURIFY THE INDUCER ACTIVITY. THE YIELD AND SPECIFIC ACTIVITY OF THE INDUCER THUS OBTAINED WILL BE DETERMINED ALONG WITH AN EVALUATION OF THE BIOLOGICAL ACTIVITY. THIS INCLUDES ANALYSIS OF HL-60 CELL DIFFERENTIATION TO MATURE MONOCYTIC CELLS AS JUDGED BY CELLULAR MORPHOLOGY, DIFFERENTIATION ANTIGENS, EXPRESSION OF MEMBRANE COMPLEMENT RECEPTORS, PHAGOCYTOSIS, ETC. SIMULTANEOUS ANALYSIS OF CELLULAR PROLIFERATION WILL BE INVESTIGATED BY CELL CYCLE PHASE KINETICS WITH FLOW CYTOMETRY. THE PURITY OF THE INDUCER OBTAINED WILL BE EVALUATED BY GEL ELECTROPHORESIS, COLUMN CHROMATOGRAPHY, AND HPLC. THESE TECHNICAL PROTOCOLS WILL FORM THE BASIS FOR SCALED UP PRODUCTION WHICH IS NECESSARY FOR FURTHER EVALUATION OF THE IMMUNE REGULATORY EFFECTS OF THIS LYMPHOKINE AS WELL AS ITS DEVELOPMENT AS A POTENTIAL ANTILEUKEMIA THERAPEUTIC.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government